We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck plans to acquire cancer drug developer VelosBio for $2.75 Billion, expanding its presence in antibody-drug conjugates (ADCs), a new class of biological drugs. Read More
Dr. Reddy’s Laboratories, one of India’s largest pharmaceutical companies, announced Thursday that it has temporarily shut down all of its data center services in response to a cyberattack. Read More
Novavax announced Wednesday that it has reached an agreement with Australia that will see the company supply 40 million doses of its COVID-19 vaccine candidate for the country. Read More
Sanofi announced that it is acquiring a portfolio of cell immunotherapies under development to treat various cancers through the purchase of Amsterdam-based biopharma Kiadis for $358 million. Read More
The FDA plans to channel more resources to the Center for Biologics Evaluation and Research (CBER)’s Cell and Gene Therapy Program (CGTP) to deal with its rapidly growing workload, agency officials said at the first round of public meetings on the next reauthorization of the Prescription Drug User Fee Act (PDUFA). Read More
Catalent is expanding its cell therapy product line by adding ALLOB, an investigational product derived from bone marrow cells, through the purchase of Bone Therapeutics’ cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support (SCTS). Read More
AstraZeneca is selling off the global rights for two hypertension drugs, Atacand and Atacand Plus, to German drugmaker Cheplapharm Arzneimittel in a $400 million deal covering 70 countries. Read More
The Cambridge, Mass., company is developing photoreceptor-protein-based therapies that it believes could deliver “functional vision to patients in need.” Read More